Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Immune-mediated inflammatory diseases (IMIDs) encompass several entities such as “classic” autoimmune disorders or immune-mediated diseases with autoinflammatory characteristics. Adult stem cells including mesenchymal stem cells (MSCs) are by far the most commonly used type in clinical practice. However, due to the possible side effects of MSC-based treatments, there is an increase in interest in the MSC-secretome (containing large extracellular vesicles, microvesicles, and exosomes) as an alternative therapeutic option in IMIDs. A wide spectrum of MSC-secretome-related biological activities has been proven thus far including anti-inflammatory, anti-apoptotic, and immunomodulatory properties. In comparison with MSCs, the secretome is less immunogenic but exerts similar biological actions, so it can be considered as an ideal cell-free therapeutic alternative. Additionally, since the composition of the MSC-secretome can be engineered, for a future perspective, it could also be viewed as part of a potential delivery system within nanomedicine, allowing us to specifically target dysfunctional cells or tissues. Although many encouraging results from pre-clinical studies have recently been obtained that strongly support the application of the MSC-secretome in IMIDs, human studies with MSC-secretome administration are still in their infancy. This article reviews the immunomodulatory effects of the MSC-secretome in IMIDs and provides insight into the interpretation of its beneficial biological actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Reassessment of exosome composition
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., Liebler, D. C., Ping, J., Liu, Q., Evans, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.029 · Cited by 2,975
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“MSCs produce more immunomodulatory factors in three-dimensional (3D) cultures [59].”
BackgroundZhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540 · cited 1×
“, tumor-infiltrating T-cell function), tumor cells with this unique capability are capable of suppressing and modulating inflammation-inducing activity [170,171].”
BackgroundYlÖstalo, J. H., Bartosh, T. J., Coble, K., & Prockop, D. J. (2012) · STEM CELLS · doi:10.1002/stem.1191 · Cited by 427
Reis, M., Mavin, E., Nicholson, L., Green, K., Dickinson, A. M., & Wang, X.-N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02538 · Cited by 286 · cited 3×
“EVs derived from human bone marrow MSCs inhibit dendritic cell maturation and function by expressing anti-inflammatory IL-10 and TGFβ, and decrease the production of pro-inflammatory IL-6 and IL-12p70 [39].”
BackgroundNew frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259 · cited 9×
“In murine models of T1DM, EVs that originated from bone marrow-derived MSCs resulted in a delayed onset of T1DM, the preservation of islet cells, the reduction in insulitis and T cell infiltration, the decrease in antigen-presenting cell (APC) and T cell activation, lessening the Th1/Th17 population, and a decline in…”
BackgroundInfluentialMa, Z.-J., Yang, J.-J., Lu, Y.-B., Liu, Z.-Y., & Wang, X.-X. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.814 · Cited by 155
Hyvärinen, K., Holopainen, M., Skirdenko, V., Ruhanen, H., Lehenkari, P., Korhonen, M., Käkelä, R., Laitinen, S., & Kerkelä, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00771 · Cited by 111 · cited 1×
“MSC-exosomes improve the anti-inflammatory phenotype of human regulatory macrophages by downregulating IL-22 and IL-23, thereby promoting inflammation remission [32].”
BackgroundExosomes in chronic inflammatory skin diseases and skin tumors
Wang, W., Wu, C., & Jin, H. (2019) · Experimental Dermatology · doi:10.1111/exd.13857 · Cited by 59 · cited 1×
“After systemic administration, these exosomes alleviated AD-like symptoms, and in skin lesions, the mRNA levels of IL-4, IL-31, IL-23, and TNFα were reduced [156,157].”
BackgroundLee, S., Kim, S., Chung, H., Moon, J. H., Kang, S. J., & Park, C.-G. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.06.006 · Cited by 57 · cited 2×
“Similarly, in mice, they suppress Th1 differentiation by encapsulating miR-23a-3p and post-transcriptionally controlling TGFβ receptor 2 [43].”
Background
Cited by
Teymouri, S., Yousefi, M. H., Heidari, S., Farokhi, S., Afkhami, H., & Kashfi, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-024-10163-x · Cited by 11
Metadata
- Authors
- Műzes, G., & Sipos, F.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-07-26
- Volume
- 11
- Issue
- 15
- Pages
- 2300
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4288039049
- Cited by
- 168
- References
- 14
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.